Relmada Therapeutics, Inc. (RLMD) Stock Ticker
RLMD right now
Market factors today
Unlock the full RLMD picture
About Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
RLMD stock facts
| Ticker symbol | RLMD |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $401.7M |
| CEO | Sergio Traversa |
| Employees | 17 |
| Headquarters | Coral Gables, FL, US |
| IPO date | 2014-06-20 |
| Website | www.relmada.com |
What you can see for RLMD on Tickr
Live RLMD price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the RLMD report.
Rankings
FAQ
What is the ticker symbol for Relmada Therapeutics, Inc.?
The ticker symbol for Relmada Therapeutics, Inc. is RLMD, listed on the NASDAQ.
What is RLMD?
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone,…